Insider Selling: Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells 3,499 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIXGet Free Report) CFO Houte Hans Van sold 3,499 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $12.83, for a total transaction of $44,892.17. Following the transaction, the chief financial officer now directly owns 68,333 shares in the company, valued at approximately $876,712.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Houte Hans Van also recently made the following trade(s):

  • On Tuesday, April 30th, Houte Hans Van sold 1,387 shares of Nurix Therapeutics stock. The shares were sold at an average price of $12.04, for a total transaction of $16,699.48.
  • On Friday, February 16th, Houte Hans Van sold 6,812 shares of Nurix Therapeutics stock. The stock was sold at an average price of $10.02, for a total transaction of $68,256.24.

Nurix Therapeutics Trading Up 0.4 %

Shares of NRIX stock opened at $12.78 on Friday. Nurix Therapeutics, Inc. has a 12 month low of $4.22 and a 12 month high of $18.12. The stock has a 50 day moving average of $13.86 and a 200-day moving average of $9.92.

Nurix Therapeutics (NASDAQ:NRIXGet Free Report) last announced its earnings results on Wednesday, April 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.04. Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. The business had revenue of $16.59 million for the quarter, compared to analyst estimates of $14.58 million. As a group, sell-side analysts expect that Nurix Therapeutics, Inc. will post -3.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in NRIX. ARK Investment Management LLC grew its position in Nurix Therapeutics by 23.2% during the fourth quarter. ARK Investment Management LLC now owns 3,194,999 shares of the company’s stock worth $32,972,000 after buying an additional 601,952 shares in the last quarter. Affinity Asset Advisors LLC grew its holdings in shares of Nurix Therapeutics by 176.0% during the 4th quarter. Affinity Asset Advisors LLC now owns 690,112 shares of the company’s stock worth $7,122,000 after purchasing an additional 440,112 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Nurix Therapeutics by 48.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 568,576 shares of the company’s stock valued at $4,469,000 after purchasing an additional 184,617 shares during the period. GSA Capital Partners LLP raised its stake in shares of Nurix Therapeutics by 1,012.4% in the third quarter. GSA Capital Partners LLP now owns 195,420 shares of the company’s stock valued at $1,536,000 after purchasing an additional 177,852 shares in the last quarter. Finally, Kennedy Capital Management LLC lifted its position in Nurix Therapeutics by 192.7% in the third quarter. Kennedy Capital Management LLC now owns 163,623 shares of the company’s stock worth $1,286,000 after purchasing an additional 107,719 shares during the period.

Wall Street Analyst Weigh In

NRIX has been the topic of several recent research reports. Needham & Company LLC restated a “buy” rating and set a $31.00 target price on shares of Nurix Therapeutics in a report on Tuesday, April 9th. HC Wainwright reduced their target price on Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a report on Tuesday, February 20th. Royal Bank of Canada increased their price target on Nurix Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a report on Thursday, April 11th. Morgan Stanley upped their price objective on shares of Nurix Therapeutics from $9.00 to $10.00 and gave the stock an “equal weight” rating in a report on Monday, February 26th. Finally, Robert W. Baird raised their target price on shares of Nurix Therapeutics from $24.00 to $25.00 and gave the company an “outperform” rating in a research note on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $21.33.

Get Our Latest Analysis on NRIX

Nurix Therapeutics Company Profile

(Get Free Report)

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Featured Stories

Insider Buying and Selling by Quarter for Nurix Therapeutics (NASDAQ:NRIX)

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.